China Pharma Holdings Inc. (CPHI)
CPHI trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/0001213900-26-038521-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CPHI on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | China |
| IPO year | Not reported by the screener |
| SEC CIK | 0001106644 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.1M |
| Net income | -$3.2M |
| Operating income | -$3.2M |
| Net margin | -76.9% |
| Operating margin | -78.2% |
| Revenue growth | -8.5% |
| Cash | $345K |
| Total assets | $31.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 5.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-14 |
| Cash and burn | $305K cash; operating cash flow -$35K a quarter. | Report 2026-06-30 |
| Shares outstanding | 43,022,002 (2026-08-11); 3,262,002 a year earlier; 11,432,801 three years earlier. 3y figure adjusted for splits (1-for-50 overall). | Cover page 2026-08-11 |
| Reverse splits, 3 years | 2; latest 1-for-10 on 2025-04-15 | Source 2025-04-15 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-07-23 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | ENROME LLP, Singapore, Singapore | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-04-01 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $948K | -$1.5M | -$33K | $305K | $1.6M | $3.9M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $984K | -$1.1M | -$55K | $168K | $1.5M | $4.0M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $1.2M | -$1.2M | $152K | $345K | $1.4M | $4.1M | 10-K 2026-04-01 |
| Q3 2025 2025-09-30 | $756K | -$651K | -$204K | $268K | $1.4M | $4.1M | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $1.0M | -$528K | $274K | $600K | $1.4M | $4.4M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $1.1M | -$786K | -$74K | $400K | $1.2M | $4.3M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $1.1M | -$1.2M | $299K | $627K | $1.1M | $4.5M | 10-K 2026-04-01 |
| Q3 2024 2024-09-30 | $1.1M | -$1.1M | -$47K | $700K | $315K | $5.5M | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-07-23 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-04-01 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-08-14 |
| Latest current report CURRENT REPORT | 8-K | 2026-07-22 |
| Latest proxy DEFINITIVE PROXY STATEMENT | DEF 14A | 2026-11-10 |
Source: SEC EDGAR submissions feed, 427 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.8% |
| 1 month | -30.7% |
| 3 months | -52.3% |
| Year to date | -57.0% |
| 1 year | -65.8% |
| From 52-week high | -93.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IGC | IGC Pharma Inc. | $0.1750 | -0.57% | $20.4M |
| TXMD | TherapeuticsMD Inc. | $1.81 | -3.21% | $20.9M |
| SHPH | Shuttle Pharmaceuticals Holdings Inc. | $4.24 | -6.40% | $20.2M |
| CELU | Celularity Inc. | $0.6191 | -1.75% | $20.1M |
| AYTU | Aytu BioPharma Inc. | $1.82 | +1.68% | $19.8M |
| ATOS | Atossa Therapeutics Inc. | $1.93 | -1.53% | $19.3M |
| COCP | Cocrystal Pharma Inc. | $0.9777 | -0.24% | $18.8M |
| RNAZ | TransCode Therapeutics Inc. | $1.35 | -1.46% | $22.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier